Researchers report typhoid vaccine antibodies lasting 5 years in Nepalese children
A follow-up study found that most children retained a strong antibody response five years after one vaccine dose.
High evidenceHuman studySome caution advised
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
The study included 20,019 children aged 9 months to 16 years who were initially assigned to receive either a typhoid conjugate vaccine or a meningococcal vaccine. A subgroup of 1,500 children provided blood samples from vaccination through Year 5 to assess antibodies against typhoid vaccine components.
The average anti-Vi IgG antibody concentration declined from 2037.90 at Day 28 to 109.3 at Year 5. Even so, 88% of participants still had at least a fourfold rise from their baseline antibody level at Year 5. Antibody levels declined faster in younger children than in older children, but the study did not determine whether booster doses are needed or how antibody levels relate to actual typhoid disease.
The question examined
Researchers examined how long immune responses lasted after one dose of Typbar TCV, a typhoid conjugate vaccine, in children in Lalitpur, Nepal. The parent study was a participant- and observer-blinded randomized trial conducted from 2017 to 2021, involving 20,019 children aged 9 months to 16 years. For the immunogenicity follow-up, 1,500 participants—1,000 originally assigned to the typhoid vaccine and 500 to the comparison meningococcal vaccine—provided blood samples at baseline, Day 28, Month 18, and Years 2, 4, and 5. The main measure was the level of anti-Vi antibodies, which are immune markers associated with response to the vaccine.
What the trial found
The geometric mean anti-Vi IgG concentration rose to 2037.90 at Day 28 after vaccination, fell to 241.29 at Month 18, and was 109.3 at Year 5. At five years, 88% of participants still had at least a fourfold increase in antibody level compared with baseline. Antibody decline was slower among older children, females, and children who already had detectable anti-Vi IgG at baseline. Anti-Vi IgA levels were strongly correlated with IgG levels. These findings show persistence of measured antibody responses, but they do not by themselves establish how well participants were protected from typhoid disease.
Who this is relevant to
These findings most directly apply to children aged 9 months to 16 years who received the studied typhoid conjugate vaccine in a setting similar to Lalitpur, Nepal. They may not apply in the same way to adults, children in other regions, people receiving different typhoid vaccines, or populations with different prior exposure to typhoid. The study does not provide individualized guidance or establish whether any particular person needs an additional dose.
Why this matters
The findings suggest that one dose of typhoid conjugate vaccine can be followed by measurable antibody responses for at least five years in the Nepalese children studied. This information may help researchers assess the duration of vaccine responses and investigate vaccination timing and possible booster needs. Because the study measured antibodies rather than typhoid illness, the results cannot establish the exact level or duration of clinical protection.
Limitations & evidence assessment
The immunogenicity analysis included 1,500 children, rather than all 20,019 participants in the randomized trial. The abstract does not report how many participants remained at each blood-sampling visit or fully explain how later receipt of the alternate vaccine after unblinding affected the five-year antibody results. Antibody concentration is an immune marker and is not the same as confirmed protection against illness. The abstract also provides too little information to determine how well these findings apply outside the study population or how antibody levels relate to a specific need for booster doses.
Why this evidence level: Large randomized trial (detected n≈20019 ≥ 500).
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
Researchers found that disrupting 18 different autism-linked genes in human neural progenitor cells produced overlapping changes in gene activity. The results point to the X-linked gene ZFX as a possible contributor to the lower autism vulnerability seen in females, although the proposed protective effect still needs to be tested directly.
A study proposes a broader way to explain how sensory neurons use limited resources, allowing them to optimize goals other than maximizing information. Reanalyzing classic blowfly data, the researchers found that the neurons’ response pattern was better matched by reducing average square-root reconstruction error than by maximizing mutual information.
Researchers developed a way to genetically program common native gut bacteria to release therapeutic signals. In mice with a form of fatty liver disease linked to metabolic dysfunction, one engineered bacterium improved glucose control, reduced bacterial toxins in the bloodstream and lessened liver fat.
